Verastem reports 86% six-month survival rate in pancreatic cancer trial
Go back to Verastem reports 86% six-month survival rate in pancreatic cancer trial| VERASTEM SHS (NASDAQ: VSTM) | Delayed: 7.55 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.55 | 52 Week High | $2.43 | |||
| Open | $7.55 | 52 Week Low | $1.05 | |||
| Day High | $7.55 | P/E | N/A | |||
| Day Low | $7.55 | EPS | $-1.79 | |||
| Volume | 500 | |||||
